March 13, 2019

The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) is a huge mover today! The stock decreased 16.90% or $0.96 during the last trading session, reaching $4.72. About 1.77 million shares traded or 76.43% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 13.00% since March 13, 2018 and is downtrending. It has underperformed by 17.37% […]

by

DEVON, Pa., March 11, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided an overview of recent operational highlights. The Company also announced that its current […]

by

JERUSALEM, March 13, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the Company’s presentation time at Barclays Global Healthcare Conference has been changed as follows. Barclays Global Healthcare ConferenceDate:  March 12-14, 2019Company Presentation:  March 14, 2019 at 8:00 am (Eastern time)Location:   Loew’s South Beach Hotel, Miami, FLPresenter:  Jeffrey A. Meckler, Vice […]

by

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed Tuesday amid a slew of positive drivers showing institutional investors were buying shares of the neuropsychiatric pharmaceutical company. The stock also popped after CNBC’s Jim Cramer shared his outlook for the year ahead in the budding cannabis industry saying he expected “marijuana-adjacent” biotechnology companies to start getting more credit from investors […]

by

Children with Lennox-Gastaut syndrome (LGS) who were treated with the cannabinoid product Epidiolex (cannabidiol) had fewer drop seizures, according to results of a clinical trial developed by Britain’s GW Pharmaceuticals. The Phase 3 trial (GWPCARE3, NCT02224560) showed that patients taking Epidiolex saw the number of monthly seizures fall by 50 percent or more, compared to the 15 percent reported […]

by

Insys Therapeutics, Inc. filed 10-K with SEC. Read ‘s full filing at 000156459019007444. SUBSYS® is a proprietary, single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. We filed our NDA in March 2011 and received marketing approval for SUBSYS® from the FDA in January 2012 for the treatment of BTCP. […]

by

April 20 is a day to toast and get toasted, if you work for a brewery. Brewers honor the date — which is known as 420, the high holiday for marijuana users —  with pot-punny beer names, especially for IPAs. You see, cannabis and hops are relatives, and both get their flavors and aromas from compounds called […]

by

“Global Cannabidiol Products Market Is Expected To Reach Around USD 15,040 Million By 2025” report (Sample Copy Here) offers detailed insights on the market dynamic forces to enable informed business decision making and development strategy formulation supported on the opportunities present in the market. Cannabidiol Products Market report delivers the most up-to-date industry data on the actual and […]

by

“Mr. Haynes has an impressive track record in pipeline and product development which is directly relevant to FSD’s vision of becoming a global cannabinoid based pharmaceutical leader,” said Dr. Raza Bokhari, Co-chairman of the Board. “He blends world class specialty pharmaceutical experience with a fast-paced biotech mindset that will help accelerate FSD’s growth and global […]

by

INSYS Therapeutics Inc. (NASDAQ:INSY) and GTx Inc. (NASDAQ:GTXI), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation of the two firms. Earnings and Valuation Table 1 shows the gross revenue, earnings per share (EPS) and valuation […]

by

Intec Pharma Ltd. (NASDAQ:NTEC) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of the two firms. Valuation and Earnings Table 1 shows top-line revenue, earnings per share and valuation of […]

by

CLOSE An increasing number of pet owners are using cannabis-based products to treat their dogs’ ailments. Kathleen Gray, Detroit Free Press Lansing Bureau Last summer, Brad Stottelmyer called his 11-year-old dog Misty “Four Paws Walking,” a gallows tribute to the nickname that death-row inmates are given as they await their execution. The 77-pound chocolate Labrador […]

by

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had a decrease of 11.19% in short interest. NVIV’s SI was 249,300 shares in March as released by FINRA. Its down 11.19% from 280,700 shares previously. With 35,800 avg volume, 7 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s short sellers to cover NVIV’s short positions. The SI to Invivo […]

by